Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $24

Moomoo News · Nov 20 07:33 · Ratings

Mizuho Securities analyst Anthony Petrone maintains $ADMA Biologics (ADMA.US)$ with a buy rating, and maintains the target price at $24.

According to TipRanks data, the analyst has a success rate of 51.7% and a total average return of 9.3% over the past year.

AnalystRecentRatingAutoNews_210559_20241119_ba788d01b6632c7f9e85895530a48857ef76249c_1732105900312755_mm_en

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $24

Risk Disclaimer